Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2013; 8(04): 169-173
DOI: 10.4103/1793-5482.125658
EDITORS CHOICE

Levetiracetam seizure prophylaxis in craniotomy patients at high risk for postoperative seizures

Sankalp Gokhale
Department of Neurology, Division of Neurocritical Care, Duke University Medical Center, Durham, North Carolina 27710
,
Shariq Khan
1   Department of Anesthesiology Division of Neuro Anesthesia, Duke University Medical Center, Durham, North Carolina 27710
,
Abhishek Agrawal
2   Division of Neurosurgery, Department of Surgery and Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710
,
Allan Friedman
3   Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710
,
David McDonagh
4   Department of Anesthesiology and Neurology, Division of Neuro Anesthesiology, Duke University Medical Center, Durham, North Carolina 27710
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Background: The risk of developing immediate postoperative seizures in patients undergoing supratentorial brain tumor surgery without anti-epileptic drug (AED) prophylaxis is 15-20%. Patients who present with pre-operative seizures and patients with supratentorial meningioma or supratentorial low grade gliomas are at significantly higher risk. There is little data on the efficacy of levetiracetam as a prophylactic AED in the immediate postoperative period (within 7 days of surgery) in these patients. Methods: We conducted a retrospective chart review of 165 adult patients classified as higher risk for postoperative seizures who underwent brain tumor resection at Duke University Hospital between time May 2010 and December 2011. All patients had received levetiracetam monotherapy in doses of 1000-3000 mg/day in the immediate postoperative period. Results: We identified 165 patients with following tumor locations: Frontal 83 (50.3%), Temporal 37 (22.4%), Parietal 30 (18.2%), Occipital 2 (1.2%) and 13 (7.8%) with single lesions involving more than one lobe. Histology revealed: Glioma 98 (59.4%), Meningioma 57 (34.5%) and Brain Metastases 6 (3.6%). Preoperatively, 88/165 (53.3%) patients had presented with seizures. 12/165 patients (7.3%) developed clinical seizures (generalized 10, partial 2) in the immediate post-operative period. Other than somnolence in 7 patients (4.2%), no major side-effects were noted. Conclusions: The incidence of seizures was significantly lower in patients treated with levetiracetam (7.3%) when compared with the expected (15-20%) rate without AED prophylaxis based on the previous literature. Levetiracetam appears effective and safe for seizure prevention in patients undergoing brain tumor resection and who are at significantly higher risk of developing post-operative seizures. These findings warrant confirmation in a prospective randomized trial.

Key-words:

Antiepileptic drug - brain tumor - craniotomy - levetiracetam - perioperative - prophylaxis - seizures


Publication History

Article published online:
27 September 2022

© 2013. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India